Details of Disease

Disease Name

Vernal keratoconjunctivitis

VKC; Spring catarrh; Vernal Keratonconjunctivitis

Definition

Vernal keratoconjunctivitis (VKC) is a chronic, severe allergy that affectsthe surfaces of the eyes. It most commonly occurs in boys living in warm, dry climates. Attacks associated with VKC are common in the spring (hence the name 'vernal') and summer but often reoccur in the winter. Signs and symptoms usually begin before 10 years of age and may include hard, cobblestone-like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; andinvoluntary blinking or spasms of the eyelid (blepharospasm).The condition usually subsides at the onset of puberty. It is caused by ahypersensitivity (allergic reaction)to airborne-allergens. Management focuses on preventing 'flare ups' and relieving the symptoms of the condition.

Disease Hierarchy

DISB52BH: Eye disorder

DIS36LV6: Vernal keratoconjunctivitis

Disease Identifiers

MONDO ID

MONDO_0019085

MESH ID

D003233

UMLS CUI

C0022577

MedGen ID

9622

Orphanet ID

70476

SNOMED CT ID

317349009

General Information of Disease (ID: DIS36LV6)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cromoglicate	DM74LZK	Approved	Small molecular drug	[1]
Hyoscyamine	DM804UR	Approved	Small molecular drug	[2]
Lodoxamide	DMTY2K8	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CHIA	TTJB1O0	Limited	Altered Expression	[4]
TSLP	TTHMW3T	Strong	Altered Expression	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCL24	OT9LGHV0	Limited	Biomarker	[6]
CCL26	OT2B7HR9	Limited	Altered Expression	[6]
GYPC	OTOEDR7O	Limited	Genetic Variation	[7]
PRAP1	OT48QD82	Limited	Biomarker	[8]
------------------------------------------------------------------------------------

References

1	Twenty-first century mast cell stabilizers. Br J Pharmacol. 2013 Sep;170(1):23-37.
2	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3	Lodoxamide FDA Label
4	Chitinase levels in the tears of subjects with ocular allergies.Cornea. 2008 Feb;27(2):168-73. doi: 10.1097/ICO.0b013e318159a950.
5	Thymic Stromal Lymphopoietin-Related Allergic Pathway in Patients With Vernal Keratoconjunctivitis.Cornea. 2019 Mar;38(3):344-351. doi: 10.1097/ICO.0000000000001832.
6	Evaluation of eotaxin-1, -2, and -3 protein production and messenger RNA expression in patients with vernal keratoconjunctivitis.Jpn J Ophthalmol. 2009 Mar;53(2):92-99. doi: 10.1007/s10384-008-0628-5. Epub 2009 Mar 31.
7	Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients.Jpn J Ophthalmol. 2007 Sep-Oct;51(5):332-337. doi: 10.1007/s10384-007-0461-2. Epub 2007 Oct 5.
8	Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1364-70. doi: 10.1167/iovs.04-1196.